The Center for American Indian Health has been featured in a new article published online by the Johns Hopkins Bloomberg School of Public Health, titled “A New Shot Prevents Serious Illness from RSV.” The article discusses a new product called Nirsevimab, which has recently been shown in clinical studies to significantly reduce severe illness from respiratory syncytial virus (RSV). The […]

Findings published in the New England Journal of Medicine show a new, long-acting antibody protected infants throughout the respiratory syncytial virus (RSV) season with a single dose. The antibody is nirsevimab, and the findings from the MELODY trial show one dose provides babies with rapid and direct protection against RSV disease during the five-month RSV […]